Search results for PX-TA1365

Tafasitamab Biosimilar – Anti-CD19 mAb – Research Grade, ProteoGenix, PX-TA1365

Description of Tafasitamab Biosimilar - Anti-CD19 mAb - Research Grade General information on Anti-CD19[Homo sapiens] (Tafasitamab) Monoclonal Antibody Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells.